Glutamine Suppletion Minimizes the Atrial Fibrillation Burde

Completed

• Conditions: Atrial fibrillation; 10007521

• Registration Number: NL-OMON46467
• Lead Sponsor: Cardiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Adult (>18 years), frequent (>1/week) symptomatic atrial fibrillation

Exclusion Criteria

Diabetes mellitus, soya, gluten or shell fish allergy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary study parameters are the HSP levels of HSP27 and HSP70 in blood at<br /><br>baseline, after 3 months and after 6 months. Main endpoint is completion of 6<br /><br>months follow-up period.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters are the AF incidence and burden at baseline, after 3<br /><br>months and after 6 months. Furthermore the correlation between the HSP levels<br /><br>and the AF incidence and burden will be derived at baseline, after 3 months and<br /><br>after 6 months. </p><br>